China’s Bribery, Spotty Drug Distribution And IP Gaps Equals … Great Opportunities?
This article was originally published in PharmAsia News
Executive Summary
It is no secret that China is seen as a key growth market for the pharmaceutical industry. But as appealing as the country's skyrocketing market is to companies, many barriers to expansion, including IP concerns and a slowly improving drug distribution system - remain